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Purpose of the Study
Although HAART has greatly impacted treatment of HIV
infection, lipodystrophy and HIV wasting still represent
unsolved problems in HIV therapy and patient care.
Oxymetholone, a testosterone derivative, has been shown
to promote weight gain in AIDS-associated wasting.
Methods
We analyzed the effects of oxymetholone [50 mg BII) and
TII)] in a randomized (1:1:1), double-blind, placebo-con-
trolled phase III study with 92 subjects (all on ART) expe-
riencing unintended weight loss>10% of ideal weight
according to Broca with special emphasis on body compo-
sition measurement 80 patients (69 men,11 women,
mean age:38,8 years) completed the 16-week double-
blind study phase.
Results
Mean weight gain was +3.7 ± 3.5 kg and +3.1 ± 2.7 kg in
the oxymetholone groups [BII); n = 25 vs TII); n = 27] as
opposed to +0.97 ± 3.4 kg in the placebo were observed in
body cell mass (30.6 before vs 32.5 after therapy), lean
body mass [56.3 before vs 59.0 after therapy in the BII)
group] and body mass index (21.4 before vs 22.1 after
therapy) exclusively in oxymetholone-treated patients.
The extracellular mass to body cell mass ratio,(p <
0,0001). Total body fat was unchanged by oxymetholone
treatment. Adverse events were mainly hepatic occurring
in 14% of oxymetholone-treated patients with significant
elevations of AST, ALT and GGT;2 patients (7.4%) in the
BII) arm experienced grade 3 and 4 liver toxicity com-
pared with 6 [21.4%) in the TII] arm.
Conclusion
Oxymetholone was found to have true anabolic effects in
a double-blind, placebo-controlled phase III trial. The
(BII) (100 mg/d) regimen appeared equally effective to
TII) (150 mg/d) dosing while displaying reduce liver tox-
icity. Due to its favourable protein anabolism, it may be
recommended for therapy of wasting and lipodystrophy I
HIV-infected subjects.
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